Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a blood test predict brain recovery after stroke?

NCT ID NCT04971564

Knowledge-focused Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at blood markers related to inflammation and clotting in people with brain oxygen deprivation from stroke or bleeding. Researchers will compare these markers between patients with brain hypoxia and those without. The goal is to see if these markers are linked to how well patients recover over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict outcomes after stroke or brain bleeding using simple blood tests.
What could go wrong
This is an observational study, not a treatment trial. It may not find clear links between the biomarkers and patient recovery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients treated at the Rothschild Foundation Hospital within the first 24 hours of an acute neurological symptomatology

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- For cases, admitted within the first 36 hours of an acute neurological symptom related to : * An ischaemic cerebrovascular accident (iCVA) eligible for a mechanical thrombectomy procedure, * A subarachnoid haemorrhage (SAH, all aetiologies) : patient presenting with at least a modified Fisher scale 3 or 4, * An intra-parenchymal haematoma (IPH) with greatest axis ≥ 20mm or with NIHSS on admission \>4. OR * For control patients, admitted within 7 days of the onset of acute neurological symptomatology related to a clinical diagnosis of transient ischaemic attack (TIA) - based on thorough questioning of the patient on admission - and prior to imaging, with an ABCD2≥ 2 score. * Express consent to participate in the study. * Member or beneficiary of a social security. Exclusion Criteria: * Pre-existing functional and/or cognitive disability * Patient under legal protection. * Pregnant or breastfeeding woman. * Patient with secondary haemorrhagic transformation. Secondary exclusion criteria : * Patients with an ischaemic lesion visible on imaging, unrelated to large vessel occlusion and therefore ineligible for mechanical thrombectomy. * Patients diagnosed with an acute non-vascular neurological pathology (migraine, epilepsy, etc.). * TIA patients presenting an abnormality on follow-up imaging 24-48 hours after the initial imaging. Excluded patients will be replaced.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebral hypoxia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain hypoxia - ischemia Hypoxia, Brain intracerebral hemorrhage ischemic stroke subarachnoid hemorrhage transient ischemic attack

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cerebral hypoxia Ischemic stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Fondation Adolphe de Rothschild

    RECRUITING

    Paris, Île-de-France Region, 75010, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.